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In the United States, colorectal cancer (CRC) is the third leading cause of death from 
cancer. Promising research has shown the chemopreventive effects of folic acid (FA) on 
CRC. Folate is a water-soluble B vitamin that is essential in the transfer of one-carbon 
necessary for DNA synthesis and methylation reactions. Because folate is essential in 
DNA replication, a deficiency can predispose cells to neoplastic transformation. While 
folate depletion in normal tissues can predispose them to becoming cancerous, 
researchers discovered that folate depletion in colon cancer cells might suppress the 
progression of current neoplasms, decreasing cell proliferation. The current study 
investigated the role of FA and its metabolites on CRC cell proliferation, apoptosis, cell 
cycle regulation and metastasis. We demonstrated that FA did not regulate proliferation 
in several different colon cancer cell lines. FA did not influence cell cycle regulation, 
apoptosis or metastasis in HCT116 cells. In addition, we observed that FA decreased 
expression of proteins involved in epithelial-mesenchymal transition (EMT) in A549 lung 
cancer cells. Metabolites of FA, including dihydrofolic acid (DHF) and tetrahydrofolic 
acid (THF), did not significantly affect HCT116 cell proliferation or cell cycle regulation. 
This study suggests that FA and its metabolites do not regulate colon cancer. Further 
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Chapter 1: Background 
1.1 Introduction  
Cancer is among one of the leading causes of death in the world (1). In the United 
States, colorectal cancer is the third leading cause of death from cancer (2). In 2016, it is 
estimated that there will be about 134,000 new cases of colon and rectal cancer (3). 
Additionally, about 35 to 50% of Americans over 50 years old already have one or more 
adenomas in their colon. Many of these adenomatous growths lack any signs or 
symptoms, making the detection more difficult (4, 66). Therefore, early detection and 
chemoprevention is important to the colon cancer-related death rate. The incidence of 
colon cancer is highly associated with diet. The proposed strategies to reduce the risk of 
developing colorectal cancer (CRC) include limiting red and processed meats, avoiding 
alcohol and smoking, consuming more vegetables and fruits, avoiding obesity, and 
obtaining adequate calcium and vitamin D (2). Recently, a significant correlation 
between folate intake and occurrence of CRC has been reported, suggesting a role of 
adequate folate intake for colon cancer prevention (4, 23).  
1.1.1 Diet and CRC 
There is a strong relationship between dietary intake and the risk of developing 
CRC. A study by Doll and Peto found that dietary intake might be responsible for about 
90% of colon cancer deaths in the US (5). A plant-based diet rich in vegetables and low 
in red meat is associated with a decreased risk of CRC (49). Some protective nutrients 
include vitamin D, folate, calcium, and certain antioxidants such as β-carotene, vitamin C 
and gamma-tocopherol (50). A study in women found that those who had diets rich in 
  2 
fruits and vegetables had a significantly reduced risk of developing CRC than women 
who did not (51). In addition, a high consumption of meat and animal fat could increase 
the risk of developing CRC. A diet high in fruits, vegetables and whole grains was found 
to be protective against CRC (6). 
1.1.2 Effect of folate on CRC 
Folate has been shown to prevent the development of colon cancer (23). The 
potential chemopreventive role of folate may be due to its prevention of aberrations in 
DNA synthesis and methylation that can lead to colorectal carcinogenesis (7). However, 
studies have shown that after the mandatory folic acid (FA) fortification in flour and 
grains, the incidence of colon cancer increased (4, 23). These studies have only 
demonstrated an observational relationship and cannot prove causation. Due to the 
seemingly conflicting evidence to support this relationship, the effect of folate on CRC is 
still under exploration.  
1.2 Folate Metabolism and health 
1.2.1 Folate nutrition  
Folate is a B vitamin that is fundamental in many biochemical reactions due to its 
ability to transfer one-carbon molecules. The body cannot synthesize this nutrient, so it 
must be obtained from dietary sources, such as leafy green vegetables and legumes (8). 
Folic acid is the synthetic form used for supplementation and fortification in foods while 
folate is the natural form. Folic acid is about 70% more bioavailable than folate for 
absorption in the small intestine (9). To assess short-term folate status in humans, serum 
folate concentration is measured, with a level of 3 ng/mL being sufficient. To assess 
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long-term folate status, erythrocyte folate concentration is measured. Recommended 
Dietary Allowance (RDA) of folate for adults is 400 μg DFE/d, with the Tolerable Upper 
Intake Level (UL) set at 1,000 μg DFE/d. According to the 2003–2006 National Health 
and Nutrition Examination Survey, most individuals obtain the recommended amount of 
folate, but some groups are still at risk of deficiency, such as women of childbearing age 
and non-Hispanic black women (10, 52). 
1.2.2 Absorption  
The absorption mechanism for FA is a complex process and has been under 
investigation during the last decade. Folates are primarily absorbed in the duodenum and 
jejunum, but also in the colon. The process involves a pH-dependent and carrier-mediated 
mechanism through the human colonic luminal membranes. There are two main carriers, 
reduced folate carrier (RFC) and proton-coupled folate transporter (PCFT). RFC has a 
high affinity for 5-methyltetrahydrofolate and 5-formyltetrahydrofolate, while PCFT has 
a high affinity for folic acid. PCFT is expressed at a much lower level in the colon 
compared to the small intestine. However, high levels of folate transport occur in the 
proximal and distal colonic brush-boarder membranes (11).   
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1.2.3 Metabolism 
 
Figure 1.2.1 Folate One-Carbon Metabolism. Folate is fundamental in the process of 
DNA synthesis and methylation reactions. DHF, dihydrofolate; THF, tetrahydrofolate; 
MTHFR, methyltetrahydrofolate reductase; MS, methionine synthase; SAM, S-
adenosylmethionine; SAH, S-adenosylhomocysteine; TS, thymidylate synthase; dUMP, 
deoxyuridine monophosphate; dTMP, deoxythymidine monophosphate  
Folate is an essential factor in one-carbon metabolism in the body. The pathway 
involves DNA synthesis and methylation. In the first step, folate is converted to 
dihydrofolate (DHF) by dihydrofolate reductase (DHFR) in a slow reaction. DHF is then 
converted to tetrahydrofolate (THF) by DHFR in a fast reaction, and is subsequently 
converted into 5,10-methyltetrahydrofolate (5,10-methylTHF) through several steps of 
chemical modifications (12). In the methionine cycle, 5,10-methylTHF acts as a methyl 
donor of methionine synthase (MS), converting homocysteine to methionine and 
producing S-adenosylmethionine (SAM). SAM is an essential methyl donor in many 
reactions, such as the methylation of DNA, RNA, proteins and lipids (8). 5-methylTHF is 
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converted to tetrahydrofolate (THF) and then to 5,10-methyleneTHF by serine 
hydroxymethyltransferase (SHMT). SHMT also catalyzes the interconversion of serine to 
glycine. 5,10-methyleneTHF is used for the methylation of deoxyuridine monophosphate 
(dUMP) to deoxythymidine monophosphate (dTMP), catalyzed by thymidylate synthase 
(TS) (12). dTMP is the only source of thymidine in the cell and is the rate limiting step 
for DNA synthesis (13). In addition, both THF and 5,10-methyleneTHF can be used for 
purine synthesis via addition of a formyl group (12).  
1.2.4 Unmetabolized folate 
 An excess or deficiency of folic acid (FA) can have negative impacts on the 
health of individuals by interrupting folate homeostasis. A high intake of FA can increase 
the release of unmetabolized FA into the plasma (14). For FA to be incorporated into 
one-carbon metabolism, it must first be reduced to tetrahydrofolate (THF) (12). When 
there is an excess amount of FA, the body cannot metabolize it fast enough and 
unmetabolized FA can accumulate. Although some studies suggest that unmetabolized 
FA could increase the risk of certain conditions, other studies suggest that there are no 
harmful effects (14, 60, 61). One study demonstrated that unmetabolized FA was linked 
to a decline in immune function in postmenopausal women (60). Additionally, circulating 
unmetabolized FA was linked to lower cognitive test scores in older adults (61). In a 
case-control study conducted by Cho et al. (2015), unmetabolized FA was not associated 
with an increased colon cancer risk. Future studies are essential to understand the impact 
that unmetabolized FA has on the risk of chronic disease. 
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1.2.5 Health complications 
Several negative health consequences are associated with folate deficiencies, 
including neural tube defects (NTDs) in newborns. In 1996, the Food and Drug 
Administration (FDA) published regulations requiring the addition of FA to flour to help 
reduce NTDs (13). After the mandatory fortification of FA, the incidence of NTDs 
significantly declined. It is estimated that fortification averts about 1,000 cases of NTDs 
each year (15). A study by Mulinare et al. found vitamin supplements containing 0.8 mg 
of FA reduced the risk of NTDs by about 60% (16).  
Inadequate folate intake is also associated with megaloblastic anemia. This form of 
anemia occurs when the bone marrow creates immature and unusually large red blood 
cells, ultimately leading to a low red blood cell count. Folate is essential for the 
maturation of precursor megaloblastic cells to mature red blood cells. As a result of folate 
deficiency, an increase of immature megaloblasts and decrease of red blood cells leads to 
anemia (17).  
Additionally, folate deficiency has been linked to an increased risk of cognitive 
impairment (18). This relationship may be due to elevated serum homocysteine levels, 
also known as hyperhomocysteinemia (53). Normally, homocysteine is converted to 
methionine through a folate-dependent remethylation reaction (8). Another nutrient 
essential in this process is vitamin B12. When folate or vitamin B12 levels are low, the 
reaction is compromised and homocysteine builds up in the plasma (53). Studies have 
shown that plasma homocysteine levels are positively correlated with cognitive decline 
(56-58). In addition, a systematic review of case-control studies demonstrated that folate 
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and vitamin B12 levels were lower and homocysteine was higher in Alzheimer’s disease 
subjects than in the healthy controls (54). Additionally, a large cohort of older adults was 
analyzed to examine the effects of dietary B vitamins and the long-term incidence of 
dementia. The researchers found that higher intakes of folate reduced the risk of 
dementia, while vitamin B6 and B12 had no effect (59). Although there is promising 
research on the effect of folic acid on cognition, a causal relationship has not been 
established. 
Poor folate status is also associated with heart disease and stroke due 
to hyperhomocysteinemia, defined as levels above 15 μmol/L in the blood (8, 19). 
Inadequate folate and vitamin B12 intake can increase homocysteine levels (53). In the 
1990’s, homocysteine was first recognized as a risk factor of heart disease. As research 
has developed, the mechanism behind this relationship has been unveiled. Researchers 
believe that hyperhomocysteinemia causes endothelial cell damage and increased 
permeability and decreased flexibility of blood vessels, which increases the risk of heart 
disease and stroke (19). A study in older adults demonstrated that poor folate and vitamin 
B12 status was related to cardiovascular disease due to elevated homocysteine levels 
(55). Overall, intake of optimal folate remains a beneficial public health intervention in 
the US to prevent against numerous conditions.  
1.3 Folate and CRC 
A deficiency of folate can increase the risk of developing several malignancies, 
specifically CRC. Due to its involvement in DNA synthesis, a FA deficiency can lead to 
DNA strand breaks, uracil misincorporation, chromosomal breakage, and impaired DNA 
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repair (20). The misincorporation of uracil is likely due to the reduced methylation of 
dUMP to dTMP, increasing the levels of deoxyuridine triphosphate (dUTP) in the cell. 
This subsequently causes the incorporation of uracil into the DNA in place of thymidine, 
leading to compromised DNA integrity and increased cancer risk (21). In addition, a 
folate deficiency can increase homocysteine levels due to the lack of 5'-methyl-THF, a 
compound essential for the conversion of homocysteine to SAM (9). The increase in 
homocysteine causes an increase in S-adenosylhomocysteine (SAH) levels, which is an 
inhibitor of methylation reactions (13). Low folate status can also cause hypomethylation 
in DNA, proteins and lipids due to a reduction in SAM and an increase in SAH. 
Hypomethylation may upregulate the expression of oncogenes and lead to cancer 
progression (8). It is evident that consumption of appropriate folate is essential in the 
prevention of cancers, including CRC.  
FA is known to play an essential role in cancer prevention. Some epidemiological 
studies have shown an inverse relationship between adequate folate intake and colon 
cancer risk (4, 23). An in vitro study using HCT116 colon cancer cells showed that FA 
acted as a chemopreventive agent by downregulating insulin-like growth factor-I receptor 
(IGF-IR) (22). Another proposed chemopreventive mechanism is the prevention of uracil 
misincorporation and DNA breakage by allowing normal synthesis of thymidylate and 
purine. These nucleotides are crucial in the synthesis, replication and repair of DNA. 
Proper DNA replication and repair is necessary to prevent mutations that ultimately can 
cause cancer. FA also allows for the production of SAM, which is the methyl donor for 
DNA methylation (23). Adequate FA prevents alterations in DNA methylation, which 
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can promote tumor formation and cancer. While adequate folate intake is known to be 
chemopreventive, a folate deficient diet can lead to the development of CRC. 
In contrast to the chemopreventive effect of FA, high folate intakes may lead to an 
increased cancer risk (62, 65). After the mandate of FA fortification in flour, levels of 
folate in the plasma increased by about 2-fold (63-64). The increase in plasma folate 
levels in the US corresponded to an increase in the rate of CRC (4). An animal study 
demonstrated that increased FA intake increased the formation of tumors in animals that 
already had neoplastic foci (65). Additionally, in a double blind placebo-controlled trial, 
researchers reported that individuals consuming 1 mg/day of FA had an increased risk for 
advanced lesions and adenomas compared to a control group (62). Mason et al. (2007) 
speculated that the increase of FA in the food supply might lead to the conversion of 
adenomas into cancer.  
Additionally, folate depletion in cancerous tissues may suppress the progression of 
colon cancer (20). A study led by Novakovic et al. (2006) examined the expression of 
specific cancer-related genes that regulate cancer development during folate depletion. 
The folate deficient cancer cells demonstrated a significant decrease in growth compared 
to the folate sufficient cells. They proposed that the inhibitory role of folate depletion in 
cancer invasion and metastasis was due to the down regulation of VEGF, a growth factor 
known to promote migration of endothelial cells (20). Further studies should be 
conducted to explain this correlation. 
Folate supplementation can have dual effects depending on the stage of colon cancer 
development. While folate deficiency in normal tissues can predispose them to neoplastic 
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transformation, folate depletion in cancerous cells may suppress the progression of 
current neoplasms (20). In colon cancer cells, DNA replication and repair occur at an 
accelerated rate compared to normal healthy cells. When folate metabolism is disrupted 
during folate depletion, DNA synthesis in the cancer cells is disrupted leading to an 
inhibition of cancer cell growth (12). Therefore, the function of folate in DNA synthesis 
makes it a likely growth factor for cancer cells (4). Several studies have shown that the 
timing and dose of folate during carcinogenesis can be very important in chemotherapy 
(23). One chemotherapeutic approach is to use anti-folate agents to suppress the 
progression of existing neoplasms (20). For example, methotrexate is an analog of FA 
used to inhibit dihydrofolate reductase for chemotherapy (24).  Folate depletion may also 
act synergistically with other medications, such as alkylating agents, to increase DNA 
strand breaks. Therefore, folate deficiency can have different effects on colon cancer 
development depending on the state of the individual (20).  
In contrast, various studies have demonstrated that FA has no effect on CRC risk (14, 
42, 43, 47). In a cohort study by the American Cancer Society, researchers measured 
intakes of both natural folate and FA and examined their relationship to CRC risk. The 
researchers determined that dietary fortification with FA did not increase the risk of CRC 
(42). Additionally, a case-control study was conducted to determine the relationship 
between plasma folate levels, a sensitive indicator of dietary folate, and the risk of CRC. 
Over 38,000 individuals were followed for 11.5 years. The researchers reported that 
plasma folate was not related to the risk of CRC (47). Overall, there is conflicting 
evidence on the role of FA in CRC. Therefore, more research is warranted to understand 
this complex relationship. 
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1.4 Hallmarks and mechanisms of CRC progression 
1.4.1. General features of CRC  
Cancer arises from cells when they undergo aberrant gene expression and 
transformation. These genetic defects cause abnormal gene expression that provide tumor 
cells with special properties that normal cells do not have, such as rapid proliferation, 
resistance to apoptosis, formation of new blood vessels, and the ability to invade and 
metastasize from the primary tumors (26). The development of CRC starts as a benign, 
non-cancerous polyp inside the lining of the colon or rectum. Then the polyp invades the 
muscle layer and develops into an adenoma. It subsequently progress to an 
adenocarcinoma and carcinoma, which can metastasize or move to distant regions of the 
body (2). Currently, researchers are focusing on cancer spread because it has poor 
prognosis and is associated with 90% of cancer mortality (25).  
1.4.2 Apoptosis  
 Apoptosis is a process of programmed cell death occurring when normal cells 
undergo DNA-damage and have defective DNA repair. One of the main hallmarks of 
cancer is the ability of cells to evade apoptosis and undergo malignant transformation. 
One mechanism by which cells evade apoptosis is through the genetic disruption and up- 
or down-regulation of apoptosis-regulating genes. For example, when p53 is mutated or 
downregulated, it makes the cancer cells resistant to apoptosis in the later stages of 
tumorigenesis (27).   
 There are two main apoptotic pathways, the extrinsic or death receptor pathway 
and the intrinsic or mitochondrial pathway. The intrinsic pathway involves non-receptor-
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mediated stimuli that send intracellular signals to targets. These targets are 
mitochondrial-initiated events. The extrinsic pathway involves receptor-mediated 
interactions, including death receptors that are ligands of the tumor necrosis factor (TNF) 
superfamily. Proteins in the TNF receptor family contain “death domains”, which 
transmit death signals from the cell surface to intracellular pathways. There are several 
ways that apoptosis can be inhibited, including stimulation of inhibitors of apoptosis 
(IAP) family of proteins, caspase inhibition, poly [ADP-ribose] polymerase (PARP) 
inhibition, and Bcl-2 protein inhibition (28). PARP is a protein responsible for DNA 
repair when the cell is damaged. It is a target of caspase so PARP cleavage has been used 
as a molecular marker of apoptosis (29).  
1.4.3 Cell cycle  
The cell cycle is a process that is tightly regulated by specific cellular proteins.  The 
cell cycle is divided into G1, S, G2, and M stages. G1 is the gap phase where the cell 
prepares to enter S phase for DNA replication. The cell can either proceed to S phase, 
pause, or exit the cell cycle. The transition from one cell cycle phase to another is tightly 
regulated by expression of cyclins that activate certain cyclin-dependent kinases (CDKs) 
(30). The protein cyclin D1 activates CDK4/6 to allow transition from G1 to S phase. 
There are also several CDK inhibitors, such as p21, that inhibit CDKs and prevent the 
transition to S phase. In cancer cells, cell cycle regulation is disrupted and cells 
proliferate uncontrollably (31). For example, aberrant expression of cyclin D1 can 
directly increase cell division and contribute to tumor formation, while up-regulation of 
p21 is related to cell cycle arrest at G1/S phase (30-31). 
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1.4.4 Angiogenesis and metastasis 
 Metastasis is another hallmark of cancer characterized by the process of 
cancerous cells spreading from the original tumor location to new regions of the body and 
developing secondary tumors. The process can be divided into several main steps: 
invasion, intravasation, circulation, extravasation and formation of micro- and 
macrometastasis. In the process of invasion, malignant tumor cells lose cell-cell adhesion, 
detach from the primary tumor mass and invade the surrounding stroma. The process 
involves the release of proteases such as MMP-9 and MMP-2 that break down the 
basement membrane and extracellular matrix. (32).  
Angiogenesis is the process to form new blood vessels. As the volume of primary 
tumors increase, the cancer cells undergo the deficiency of oxygen and hypoxia-
associated necrosis. To overcome this limitation and survive, the cancer cells form new 
blood vessels through which invasive cells obtain oxygen and essential nutrients, 
permitting them to travel to distant sites. Angiogenesis is controlled by interactions 
between malignant cancer cells and normal endothelial cells. Hypoxia stimulates the 
expression of vascular endothelial growth factor (VEGF), which is a growth factor for 
endothelial cells. VEGF directly binds to its receptor (VEGFR) in the membrane of 
endothelial cells and stimulates their proliferation and subsequent formation of new blood 
vessels (33).  
1.4.5 EMT  
Recently epithelial-mesenchymal transition (EMT) is generally accepted as a 
promising mechanism of metastasis. The process permits polarized epithelial cells to 
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undergo changes to allow them to assume a mesenchymal phenotype, which promotes 
migratory and invasive characteristics. During EMT, cells lose adhesive properties, 
change the expression profile of surface proteins and release matrix-degrading enzymes. 
A decrease of E-cadherin and increase of N-cadherin is an important hallmark in the 
process of EMT and metastatic progression. E-cadherin is downregulated in almost all 
epithelial cancers and can be categorized as a tumor suppressor. In contrast, N-cadherin is 
a mesenchymal cadherin, which stimulates migration and invasion of cancer cells (32).  
EMT can be induced by various growth and differentiation factors, including 
transforming growth factor beta (TGF-β). Upon treatment with TGF-β, epithelial cells 
decrease expression of epithelial markers, such as E-cadherin, and increase expression of 
mesenchymal markers, such as N-cadherin. TGF-β signaling occurs through a complex of 
type I and type II transmembrane serine-threonine kinase receptors. The activation of the 
receptor complex leads to the phosphorylation, and subsequent activation, of SMAD2 
and SMAD3. The phosphorylated SMAD2 and SMAD3 then bind to SMAD4 and 
translocate to the nucleus to control the transcription of certain target genes, such as Snail 
and Slug. Therefore, increased phosphorylation of SMAD2 and SMAD3 has been used as 
a molecular indicator to induce EMT. In addition, increased Snail levels have been 
associated with more invasive tumor types (34). Overall, understanding the process of 
EMT and metastasis in CRC could provide insight into how metastasis could be delayed 
or prevented. 
90% of colorectal cancers develop as a result of loss-of-function mutations in tumor 
suppressor genes, including the truncation of the APC gene. The truncated APC gene 
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fails to suppress cellular overgrowth and allows for the formation of polyps in the colon 
that can develop into malignant tumors (35). The encoded protein for APC interacts with 
a variety of proteins in the cytoplasm and is involved in several cellular processes, such 
as the WNT signaling pathway. APC forms a complex with glycogen synthase kinase 3 
(GSK3), axin and casein kinase-1 (CK-1) that lead to the phosphorylation of β-catenin 
and its resulting proteasomal degradation through the 26S proteasome. Therefore, the 
dysfunction of the APC gene inhibits β-catenin phosphorylation and protects it from 
proteasomal degradation. As a result, free β-catenin translocates to the nucleus and binds 
to the TCF/LEF transcription factors to stimulate their oncogenic target genes (26).  
Due to the conflicting evidence on the role of FA in CRC, we chose to study this 
complex relationship. In the present study, we examined if treatment with FA or its 
metabolites could alter CRC cell proliferation, apoptosis, cell cycle regulation, and 
metastasis. We utilized different FA amounts, including deficient, adequate and surplus 
doses, to represent different nutritional statuses. 
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Chapter 2: Methods and Materials  
2.1 Materials 
Folic acid (FA) and dihydrofolic acid (DHF) were purchased from Sigma Aldrich (St. 
Louis, MO) and dissolved in phosphate-buffered saline (PBS). Tetrahydrofolic acid 
(THF) was purchased from Cayman Chemical Company (Ann Arbor, MI) and dissolved 
in PBS. TGF-β (240B002) was purchased from R&D Systems (Minneapolis, MN). 
Antibodies for p-GSK3β (9336s), P21 (2947s), SMAD3 (9513s), Phospho-SMAD3 
(9520s), Snail (3879s), N-cadherin (4061s) were purchased from Cell Signaling (Beverly, 
MA). Antibodies for cyclin D1 (sc-718), β-catenin (sc-1496), E-cadherin (sc-21791), 
ATF3 (sc-188), GSK3β (sc-9166), and actin (sc-1615) were purchased from Santa Cruz 
(Santa Cruz, CA). Dulbecco’s modified Eagle medium (DMEM/F-12), folate-deficient 
and folate-sufficient RPMI 1640 medium were purchased from Fisher Scientific 
(Hampton, NH). 
2.2 Cell Culture 
Human colon adenocarcinoma cells (HCT116, SW480, HCT15, HT29, and CaCO2) and 
human lung cancer cells (A549 and H358) were purchased from American Type Culture 
Collection (Manassas, VA) and grown in Dulbecco’s modified Eagle medium 
(DMEM/F-12). The medium was supplemented with 10% fetal bovine serum (FBS) 
under a humidified atmosphere of 5% CO2 at 37°C. During cell treatment, cells were 
grown in folate-deficient RPMI 1640 medium and treated with different concentrations of 
FA, DHF or THF.  
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2.3 Cell Proliferation 
Cell proliferation was assessed using the MTT [(4,5-dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium bromide] (Sigma, St. Lous, MO) method.  Cells were plated at 8000 
cells/well onto a 96-well plate in four replicates and grown overnight. Human colon 
adenocarcinoma cells HCT116, SW480, HCT15, HT29, and CaCO2 were treated with 
different concentrations of FA (0-50 µg/mL), DHF (0-20 µg/mL) or THF (0-20 µg/mL) 
in complete folate-deficient RPMI 1640 medium for 24, 48 and 72 hours at 37ºC under 
5% CO2. FA, DHF and THF were dissolved in PBS for treatment. Cells were incubated 
with 100 μL of MTT solution for 3 hours at 37ºC.  The optic density was recorded at 540 
nm using an enzyme-linked immunosorbent assay plate reader (Bio-Tek Instruments Inc., 
Winooski, VT).  
2.4 Apoptosis Assay 
HCT116 colon cancer cells were treated with different levels of FA (0-20 µg/mL) for 48 
hours at 37ºC under 5% CO2. Apoptosis was measured using a Cell Death Detection 
ELISA Kit (Roche Diagnostics, Indianapolis, IN). Attached cells were collected and 
suspended in RPMI 1640 medium. The following steps were conducted following 
manufacturer instructions. The optic density was recorded at 490 nm using an enzyme-
linked immunosorbent assay plate reader (Bio-Tek Instruments Inc., Winooski, VT). 
2.5 SDS-PAGE and Western Blot 
Cells were washed with cold 1 × phosphate-buffered saline (PBS), placed on ice for 15 
minutes in radioimmunoprecipitation assay (RIPA) buffer (Boston Bio Products, 
Ashland, MA), supplemented with protease inhibitor cocktail (Sigma Aldrich, St. Louis, 
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MO) and phosphatase inhibitor cocktail (Sigma Aldrich), and then harvested. The cell 
lysate was centrifuged at 12,000 × g for 15 min at 4°C. Protein content was measured by 
the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL). The proteins were 
separated on SDS-PAGE and transferred to nitrocellulose membranes (Osmonics, 
Minnetonka, MN). The membranes were blocked for non-specific binding in 5% non-fat 
dry milk in Tris-buffered saline containing 0.05% Tween 20 (TBS-T) for 1h at room 
temperature. Membranes were probed with specific primary antibodies in 3% Bovine 
Serum Albumin (Santa Cruz) at 4 °C overnight and then with horse radish peroxidase 
(HRP)-conjugated immunoglobulin G (IgG) for 1 h at room temperature. 
Chemiluminescence was detected with Pierce ECL Western blotting substrate (Thermo 
Scientific) and visualized by ChemiDoc MP Imaging system (Bio-Rad, Hercules, CA). 
2.6. Statistical analysis  
Statistical analysis was performed using IBM SPSS, and the data was analyzed using an 
independent sample t-test. Data was expressed as means ± SD and differences were 




Chapter 3: Folic acid (FA) and its metabolites do not affect phenotypic 
expression profiles of human colon cancer cells 
3.1 Effect of FA on cell proliferation in human colorectal cancer (CRC) cells  
One of the fundamental features of cancer is the ability of cells to proliferate abnormally.  
In the earliest stages of CRC, colon epithelial cells develop an increased proliferative 
potential (36). Previous studies have demonstrated that a FA deficiency may suppress the 
progression of existing neoplasms (20). In contrast, other studies have demonstrated that 
FA supplementation can decrease proliferation of human CRC cells (22).  It is still 
unclear if FA influences the ability of colon cells to proliferate uncontrollably.  
To examine the effect of FA on proliferation of human CRC cells, HCT116, HT29, 
HCT15, SW480 and CaCO2 cells were treated with a range of FA concentrations (0-50 
µg/ml). Several different cell lines with different genetic alterations were selected to 
encompass a variety of cancer cell mutations. For example, HCT116 cell line contains 
wild type APC, while SW480 and HT29 a have truncated APC gene. SW480, HCT15 
and HT29 express intact β-catenin, and HCT116 and CaCO-2 are β-catenin mutant cell 
lines. In addition, HCT116 and HCT15 are p53 wild type while others express mutated 
p53. A level of 0 µg/ml FA represented a deficiency, a level of 1 µg/ml FA represented 
an adequate amount, and levels above 1 µg/ml FA represented an excess amount. As 
shown in Fig 3.1 A-E, the treatment of FA did not change cell proliferation rates in all 






























































































Figure 3.1 FA had no effect on cell proliferation in 5 human colon cancer cell lines.  
Human colon cancer cells HCT116 (A), HT29 (B), HCT15 (C), SW480 (D), and CaCO2 
(E) were plated onto a 96-well plate and grown overnight. The cells were treated with 
different concentrations of FA (0-50 µg/mL) in complete RPMI Medium containing no 
FA for 24, 48 and 72 hours at 37ºC under 5% CO2. Cell proliferation was assessed by the 
MTT [(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide] method. The optic 
density was recorded at 540 nm using an enzyme-linked immunosorbent assay plate 































































3.2 Effect of FA on apoptosis in HCT116 cells 
Apoptosis is an essential process for the body to eliminate cells that are damaged or 
unneeded. When transformed cells are able to evade apoptosis, they can survive and 
undergo malignant transformation and become cancerous (37). One of the main 
hallmarks of apoptosis is the cleavage of PARP by caspases. At its full length, PARP is 
116 kD. When it is cleaved by caspase, it forms 89 kD and 24 kD fragments. The 24 kD 
fragment binds to nicked DNA and attenuates DNA repair (38). An increase in the 89 kD 
fragment serves as a marker for cells undergoing apoptosis.  
To analyze the effect of FA on programmed cell death in colon cancer cells, an apoptosis 
assay was conducted using HCT116 colon cancer cells. HCT116 cells were treated with 
0-20 µg/ml FA for 48 hours in RPMI 1640 serum free medium. Apoptosis was measured 
using a Cell Death Detection ELISA Kit. As shown in Fig 3.2A, there was no significant 
difference in the amount of apoptosis in the different cell treatments of FA. Cleavage of 
PARP was subsequently measured to confirm the Apoptosis Assay. A consistent amount 
of the full length PARP (116 kD) was observed, but the cleaved form (89 kD) was not 
detected with any of the treatment levels of FA (Fig 3.2B). 
  23
 
Figure 3.2 FA had no effect on apoptosis in HCT116 colon cancer cells. HCT116 cells 
were treated with different concentrations of FA (0-20 µg/mL) in serum free and folate-
deficient medium for 48 hours at 37ºC under 5% CO2. Apoptosis was assessed using a 
Cell Death Detection ELISA Kit (Roche Diagnostics, Indianapolis, IN). The optic density 
was recorded at 490 nm. Values are means ± SD, n = 6 (A). HCT116 cells were treated 
with different concentrations of FA (0-20 µg/mL) in serum- free and folate-deficient 
medium and incubated for 48 hours. The cells were harvested and cell lysates were 
analyzed using Western Blot. Protein levels of PARP were measured (B).  
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3.3 Effect of FA on cell cycle regulation in HCT116 cells 
The cell cycle is a process that is tightly regulated by different cellular proteins. Cyclin-
dependent kinases (CDKs) and cyclins are major regulators of the cell cycle and 
influence the cell’s fate by directing transition to S phase or G1 arrest. The protein cyclin 
D1 activates certain CDKs to allow for transition into G1 phase. There are certain CDK 
inhibitors, such as p21, that prevent the transition to G1 phase when DNA in the cell is 
damaged. Mutations in proto-oncogenes or tumor suppressor genes can promote tumor 
growth. Specifically, aberrant expression of cyclin D1 can promote G1 to S transition and 
activate cell cycle, while up-regulation of p21 inhibits the activity of CDK4/6 and leads 
to arrest of G1/S phase (30-31).  
To determine if FA influences the expression of cell cycle regulating proteins, expression 
of p21 and cyclin D1 were measured using Western Blot. The results indicate that there 
was a significant decrease in p21 protein levels at 5 µg/mL FA (p=0.03), but no other FA 
level led to a significant change (Fig 3.3A-B). Additionally, there was no significant 
change in cyclin D1 protein levels (Fig 3.3C) with increasing levels of FA. 
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Figure 3.3 FA did not affect protein levels of p21 or cyclin D1. HCT116 cells were 
treated with different concentrations of FA (0-20 µg/mL) in serum-free and folate-
deficient medium for 48 hours. The cells were harvested and cell lysates were analyzed 
using Western Blot. Protein levels of p21 were measured (A) and analyzed. Values are 




3.4 Effect of FA on beta-catenin expression 
WNT signaling is an important intracellular pathway regulating progression of colon 
cancer. The tumor suppressor gene APC is one of the key components of WNT signaling 
and is commonly (>90%) inactivated in colorectal cancer patients. In the WNT signaling 
pathway, APC binds to GSK3-β and ultimately leads to the phosphorylation of β-catenin 
and its resulting degradation. When the activity of APC is suppressed by a mutation, β-
catenin becomes active, translocates to the nucleus, and binds to certain transcription 
factors (TCFs/LEFs). This leads to the activation of certain oncogenes that promote 
tumorigenesis (26).   
HCT116 cell line contains wild type APC, making it an ideal cell line to study the WNT 
signaling pathway. Protein levels of phosphorylated GSK3-β (inactive form) were 
measured to observe the changes in WNT signaling activity (Fig 3.4A). Protein levels of 
non-phosphorylated β-catenin (active form) were also measured (Fig 3.4B). There was no 
significant difference in phospho-GSK3-β (inactive form) or non-phosphorylated β-




Figure 3.4 FA did not affect protein levels of phospho-GSK3-β or β-catenin.  
HCT116 cells were treated with different concentrations of FA (0-20 µg/mL) in serum 
free and folate deficient medium for 48 hours. The cells were harvested and cell lysates 
were analyzed using Western Blot. Protein levels of phospho-GSK3-β were measured (A) 
and analyzed. Values are means ± SD, n = 3 (B). Protein levels of non-phosphorylated 
(active) β-catenin were measured (C). 
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3.5 Effect of FA on EMT 
The process of epithelial-mesenchymal transition (EMT) is an essential process allowing 
cancer cells to metastasize or move to distant sites in the body. The process transforms 
polarized epithelial cells to cells containing a mesenchymal phenotype. This process 
increases the cancer cell’s migratory capacity, invasiveness and resistance to apoptosis. 
EMT is induced by various growth factors, including transforming growth factor beta 
(TGF-β). Upon treatment with TGF-β, epithelial cells have been shown to decrease 
expression of epithelial markers, such as E-cadherin, and increase expression of 
mesenchymal markers, such as N-cadherin. TGF-β signaling activates a receptor 
complex, which induces the phosphorylation, and subsequent activation, of SMAD2 and 
SMAD3. The phosphorylation SMAD2 and SMAD3 leads to the transcription of TGF-β 
target genes, such as Snail. In addition, increased Snail levels have been associated with 
more invasive cancers (34). 
To examine if FA can influence the ability of cancer cells to undergo EMT, we treated 
several human cancer cell lines with TGF-β and compared the morphological changes 
and TGF-β signaling. We found that all of the human cancer cell lines we tested showed 
no EMT phenotype, specifically SW480 cells (Fig. 3.5A). We speculate that all colon 
cancer cell lines we tested are insufficient models for observing TGF- β signaling, 
probably due to mutations of the type II TGF-β receptor. Therefore, we used two lung 
cancer cells line (A549 and H 358), which contain an intact TGF-β pathway and are 
commonly used as a research model for EMT. In the A549 cells, pretreatment of FA 
decreased TGF-β-induced phosphorylation of SMAD3, although there was decrease of 
total Smad3 at high doses of TGF-β (5 ug/mL) (Fig 3.5B). In the H358 cells, FA 
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treatment slightly suppressed TGF-β-induced phosphorylation of Smad 3 at high doses (5 
ug/mL) (Fig. 3.5C). As shown in figure 3.5D, treatment with TGF-β induced Snail 
expression, downregulated E-cadherin expression, and upregulated N-cadherin 
expression.  In the A549 cells, FA treatment did not influence TGF-β mediated 
upregulation of snail and downregulation of E-cadherin, but blunted TGF-β induced 





Figure 3.5 FA did not affect expression of EMT regulating genes. SW480 colon 
cancer cells were treated with 5µL of TGF-β1. Morphological changes were observed 
with microscopic imaging (A). A549 and H258 lung cancer cells were treated with 
different concentrations of FA (0, 1 and 5 µg/mL) in serum free and folate-deficient 
medium for 6 hours. Cells were co-treated with 5µL/well of TGF-β1. The cells were 
harvested and cell lysates were analyzed using Western Blot. Protein levels of phospho-
SMAD3, total SMAD3 were measured (B-C). Protein levels of Snail, E-cadherin and N-
cadherin were also measured (D).  
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3.6 Effect of FA on ATF3 protein levels in HCT116 cells 
Throughout the course of tumor progression, cells can face various stressors. Activating 
transcription factor 3 (ATF3) is a member of the ATF/CREB family of transcription 
factors, and can be induce by numerous stress signals. Recently, dichotomous activity of 
ATF3 has been reported, including apoptotic and metastatic activity (41). A study using 
HT29 and CaCO2 colon cancer cells showed that ATF3 promoted in vitro motility and 
invasion (45). In an in vivo study, overexpression of ATF3 significantly reduced the size 
of tumor xenografts in mice (46). Recently we found that ATF3 overexpression 
suppressed anti-apoptotic protein, Bcl-2, while it increased collective cell migration (39). 
Therefore, ATF3 may play a pro- and anti-tumorigenic role in colon cancer cells in a 
context-dependent manner. 
Protein levels of ATF3 were measured in HCT116 cells with different levels of FA 
treatment. There was no significant difference in protein levels of ATF3 with different 




Figure 3.6 FA did not affect protein levels of ATF3 in HCT116 cells. HCT116 cells 
were treated with different concentrations of FA (0-20 µg/mL) in serum-free RPMI 
Medium and incubated for 48 hours. The cells were harvested and cell lysates were 
analyzed using Western Blot. Protein levels of ATF3 were measured (A) and analyzed. 
Values are means ± SD, n = 3 (B). 
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3.7 Effect of dihydrofolic acid (DHF) on cell proliferation and cell cycle regulation in 
HCT116 cells 
The first step in FA metabolism is the reduction of FA by dihydrofolate reductase to 
dihydrofolic acid (DHF) (24). It is possible that FA is partially metabolized in the small 
intestine and the metabolites of FA reach colon cells to influence CRC cell growth. In 
previous studies, DHF has been shown to inhibit cell growth in Caco-2 colon cancer 
cells. The treatment of colon cancer cells with metabolites of FA, such as DHF, may 
control cancer cell growth and development.  
To understand the effect of FA metabolites on the development of CRC, HCT116 cells 
were treated with different levels of DHF. As shown in Fig 3.7A, cell proliferation rates 
did not change with different treatment amounts of DHF (0-20 µg/mL). In addition, DHF 
treatment (0-10 µg/mL) did not significantly affect proteins involved in cell cycle 




Figure 3.7 DHF did not affect HCT116 cell proliferation and expression of cell cycle-
regulating genes. HCT116 cells were plated onto a 96-well plate and grown overnight. 
The cells were treated with different concentrations of DHF (0-20 µg/mL) in complete 
RPMI Medium for 24, 48 and 72 hours at 37ºC under 5% CO2. Cell proliferation was 
assessed by the MTT method. The optic density was recorded at 540 nm using an 
enzyme-linked immunosorbent assay plate reader. Values are means ± SD, n = 4 (A). 
HCT116 cells were treated with different concentrations of DHF (0-10 µg/mL) in serum 
free RPMI Medium and incubated for 48 hours. The cells were harvested and cell lysates 





3.8 Effect of Tetrahydrofolic acid (THF) on cell proliferation and cell cycle regulation in 
HCT116 cells  
FA metabolism involves the breakdown of FA to THF through a series of reduction 
reactions. This process is essential for the use of THF in one-carbon metabolism. THF 
can then be used in DNA synthesis and repair through the formation of nucleotides. The 
compound is also essential for the metabolic reaction of homocysteine conversion to 
methionine. Methionine is subsequently transformed into S-adenosylmethionine (SAM), 
which participates in over 100 types of methylation reactions. (24). Metabolites of FA, 
such as THF, may influence the development of colon cancer depending on the level of 
the metabolite. High levels of THF may increase the ability of colon cancer cells to 
proliferate or progress through the cell cycle. In a study by Akoglu et al., 10 µg/mL of 
THF increased colon cancer cell growth after 24 hours, but the effect was not maintained 
after 48 hours (48).  
To examine the effect of THF on the proliferation of colon cancer cells, HCT116 cells 
were treated with increasing levels of THF. Different levels of THF (0-20 µg/mL) did not 
lead to a dose-dependent trend in the proliferation of colon cancer cells (Fig 3.8A). As 
shown in Fig 3.8B, proteins involved in cell cycle regulation (p21 and cyclin D1) did not 




Figure 3.8 THF did not affect HCT116 cell proliferation or cell cycle regulation. 
HCT116 cells were plated onto a 96-well plate and grown overnight. The cells were 
treated with different concentrations of THF (0-20 µg/mL) in complete RPMI Medium 
for 24, 48 and 72 hours at 37ºC under 5% CO2. Cell proliferation was assessed by the 
MTT method. The optic density was recorded at 540 nm using an enzyme-linked 
immunosorbent assay plate reader. Values are means ± SD, n = 4 (A). HCT116 cells were 
treated with different concentrations of THF (0-10 µg/mL) in serum-free RPMI Medium 
and incubated for 48 hours. The cells were harvested and cell lysates were analyzed using 
Western Blot. Protein levels of p21 and cyclin D1 were measured (B).   
  37
Chapter 4: Discussion, Conclusion, and Future Perspectives 
4.1 Discussion  
Folic acid (FA), a major dietary methyl donor, transfers one-carbon units to amino 
acids, nucleotides, and other molecules. The main function of one-carbon metabolism is 
the support of DNA synthesis and methylation reactions (24). Folate deficiency can lead 
to DNA strand breaks, uracil misincorporation, chromosomal breakage, and impaired 
DNA repair. When the integrity of the DNA is compromised, cancer risk increases, 
particularly colorectal cancer (CRC) (20). Therefore, adequate FA levels are necessary to 
allow for the proper functioning of one-carbon metabolism. 
In our study, we wanted to investigate the influence of FA and its metabolites on 
human CRC cell development. First, we observed cell proliferation in five different colon 
cancer cell lines. The cancer cells used represent cancer at the adenocarcinoma, or 
invasive stage of development. A range of FA concentrations were used to represent 
deficient, adequate, and excessive levels. A treatment level of 0 µg/mL FA represented a 
deficiency, 1 µg/mL FA represented an adequate amount, and levels above 1 µg/mL FA 
represented an excess amount. The optimal level of FA was determined because the 
RPMI medium contains 1mg/L FA to support the colon cancer cells in their ideal 
environment. In all five colon cancer cell lines spanning a variety of potential cancer 
mutations, there was no significant influence of FA on cell proliferation (Fig 3.1A-E). 
Therefore, FA may not be able to influence cancer cells once they have reached the more 
advanced stages of development.  
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Next, we observed the effect of FA on colon cancer cell apoptosis. Apoptosis is 
an essential process through which cancer cells in the body are killed in order to prevent 
further proliferation (37). An important step in the process of apoptosis is the cleavage of 
PARP by caspases (38). The Apoptosis Assay demonstrated no effect of FA on colon 
cancer cell death in HCT116 cells (Fig 3.2A). PARP protein levels demonstrated no 
cleavage of PARP, and no change in the amount of full length PARP with different 
treatments of FA (Fig 3.2B). We then analyzed the effect of FA on cell cycle regulation. 
There was a significant decrease in p21 protein levels at 5 µg/mL compared to 0 µg/mL 
FA (p=0.03) (Fig 3.3A-B). This change was not observed at any other FA treatment 
level. Additionally, there was no significant dose-dependent response. Although there 
was a significant decrease in p21, the result was not consistent when measuring cyclin D1 
levels (Fig 3.3C).  
PI3K and Wnt are significant signaling pathways in the progression of colon 
cancer. In addition, APC is a colon-specific tumor suppressor gene that is influenced by 
these signals and inhibits tumorigenesis at the early stages of transformation. In fact, 90% 
and 50% of colon cancer patients possess APC truncation and PI3K mutations, 
respectively (35). GSK3β is a major mediator of PI3K and Wnt pathways, and directly 
influences phosphorylation and proteasomal degradation of β-catenin (26). Therefore, we 
measured the phosphorylation of GSK3β at the serine 9 residue, which is an inactive 
phosphorylation site that leads to β-catenin expression (40). Overall, different levels of 
FA did not affect phospho-GSK3-β or β-catenin protein levels (Fig 3.4A-B).  
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Several studies have demonstrated that high doses of FA may enhance the 
progression of cancer in advanced stages (4, 12, 20). To test this hypothesis, we studied 
FA’s influence on the ability of cells to undergo epithelial-mesenchymal transition 
(EMT) and become metastatic. EMT allows polarized epithelial cells to lose cell-cell 
adhesion and migrate to distant areas. An important pathway in EMT is TGF-β signaling 
that causes decreased expression of epithelial markers, such as E-cadherin, and increased 
expression of mesenchymal markers, such as N-cadherin (34). In our study, we chose the 
SW480 human colon cancer cell line, which is a commonly used metastatic model in 
vitro and in vivo. Microscopic observation indicated that TGF-β did not lead to EMT (Fig 
3.5A). This is likely due to a mutation in the type II receptor of TGF-β, which is common 
in colon cancer patients. Therefore, we decided to select a small cell lung cancer model 
(A549 and H358), because they are a well-established cell line for observing EMT. Our 
results indicated that pretreatment of FA decreased TGF-β-induced phosphorylation of 
SMAD3 (Fig 3.5B), but the same observation was not made in the H358 cells (Fig 3.5C). 
To test the result shown in the A549 cells, other markers for EMT were measured 
including Snail, E-cadherin and N-cadherin. A significant change was observed in N-
cadherin, but not in other markers (Fig 3.5D). Therefore, further studies including cell 
migration and wound healing assays are required to address the inconsistent effect by FA.  
Activating transcription factor 3 (ATF3) is another protein we chose to analyze 
due to its dual roles in cancer development. ATF3 is a stress inducible gene that regulates 
homeostasis of cell proliferation, differentiation and immunity. Recently, Jiang et al. 
found that ATF3 induced apoptosis and collective cell migration in the same cell line 
(39). It has also been shown that this gene may prevent cancer cell survival at early stages 
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and promote metastasis at late stages of cancer (41). Because the expression pattern of 
this gene is very similar to the effect of FA on cancer development in terms of stage 
specificity, we explored whether different doses of FA may influence expression of this 
gene. The results indicated that FA did not influence ATF3 expression in human colon 
cancer cells (Fig3.6 A-B). 
Due to the observation that FA did not affect CRC cell growth or progression, we 
hypothesized that the effect of FA is mediated by its metabolites in the body. Thus, we 
analyzed the effects of two FA metabolites, dihydrofolic acid (DHF) and tetrahydrofolic 
acid (THF). The first step in FA metabolism is the reduction of FA by dihydrofolate 
reductase to the intermediate DHF, or completely to THF. THF can then be used in DNA 
synthesis and repair reactions. It is also needed for the conversion of homocysteine to 
methionine. Normal levels of FA and its metabolites are fundamental for DNA 
replication and repair, methionine synthesis, and methylation reactions (24). It is possible 
that FA is partially broken down in the small intestine and the metabolites of FA reach 
colonic cells to influence CRC cell growth. Additionally, previous studies using Caco-2 
cells showed that DHF and THF decrease and increase CRC cell proliferation, 
respectively (48). To examine this relationship, we first treated HCT116 cells with DHF 
and observed cell proliferation and cell cycle progression. The results from the MTT 
assay demonstrated no dose-dependent change in cell proliferation with increased levels 
of DHF (Fig 3.7A). In addition, increased levels of DHF did not affect proteins involved 
in cell cycle regulation (Fig 3.7B). We subsequently conducted a similar experiment, but 
used THF as the treatment compound. The MTT assay showed no significant effect of 
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THF on cell proliferation in HCT116 cells (Fig 3.8A). To support this result, we found 
that THF did not influence protein levels of cyclin D1 or p21 (Fig 3.8B).  
The present study suggests that FA and its metabolites do not affect CRC cell 
growth, apoptosis, or metastasis in the in vitro culture model. In support of our data, Qin 
et al. (2014) conducted a meta-analysis of randomized controlled trials. The researchers 
analyzed eight articles from PubMed and Embase databases and found that FA treatment 
was not associated with CRC risk. The results were consistent even after conducting 
subgroup analyses stratified by certain confounding variables (43). Additionally, Otani et 
al. (2007) conducted a case-control study of colorectal cancer patients. They measured 
plasma folate levels in over 38,000 patients and found no association with the risk of 
CRC in humans (47). 
Conflicting evidence shows that a high folate intake is believed to increase cancer 
risk. After the mandatory FA fortification in the US, plasma levels of FA increased along 
with the rate of colon cancer. Mason et al. (2007) hypothesized that the relationship 
between increased FA and colon cancer rates may be due to the role FA plays in DNA 
synthesis and repair. Their observations cannot prove a causal association between FA 
and increased risk of CRC because it is only observational (4). Although this relationship 
was observed, the evidence is still inconsistent and warrants further investigation. 
In contrast, Attias et al. (2006) determined that FA could decrease malignant 
transformation of colon cancer cells. They hypothesized that a FA deficiency could 
increase tumorigenic activities by altering the expression of genes related to cell cycle 
control and cell death. The researchers examined the gene expression of insulin-like 
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growth factor-I receptor (IGF-IR), which is thought to play a critical role in 
tumorigenesis. They found that FA downregulated IGF-I signaling transduction, 
potentially allowing FA to act as a chemopreventive agent (22). Although the 
experimental design was similar to our experiment, they did not confirm their data in 
other cell lines. The results must be confirmed in additional cancer cell lines, as well as in 
an in vivo model, in order to support their conclusion.   
A variety of studies have demonstrated that high FA intake does not influence the 
risk of CRC. A study conducted by the American Cancer Society analyzed the 
relationship between high levels of FA intake and CRC risk. The Cancer Prevention 
Study II Nutrition Cohort contained about 99,000 participants, with over 1,000 patients 
diagnosed with CRC during the 8-year period. The findings were consistent with other 
major studies that folate can prevent against colon cancer. In addition, the researchers 
found that there is no evidence that FA fortification increases CRC risk. This relationship 
was sustained in the group taking in the highest amount of FA at 660 μg/d (42). 
Additionally, a study conducted by Cho et al. (2015) investigated unmetabolized FA as a 
potential cause of the observed increase in CRC incidence after fortification. They 
evaluated pre-diagnostic plasma levels of unmetabolized FA in case-control studies 
within the Nurses’ Health Study. They concluded that unmetabolized FA was not 
associated with the increased risk of CRC (14).  
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Figure 4.1.1 Proposed summary of the effect of FA on CRC. FA can have different 
effects on CRC depending on the stage of cancer development.  
After reviewing the literature, we proposed a summary of the relationship 
between FA and CRC. It was previously hypothesized that FA can have dual effects on 
CRC depending on the stage of development. In normal colon cells, FA is known to 
prevent the transformation of normal cells into adenomas (23). In adenoma cells, FA has 
been shown to promote progression to later stages of development (4, 62, 65). In our 
study, we analyzed the effect of FA on apoptosis, cell growth arrest, metastasis and EMT, 
and discovered that FA did not influence cancer phenotypes in the advanced 
(adenocarcinoma) stages. We hypothesize that advanced adenocarcinoma cells with 
numerous mutations in cancer-associated genes overcome any beneficial effect of FA.  
In conclusion, our study demonstrated that FA and its metabolites have no effect 
on CRC cells in the adenocarcinoma stage. This was indicated in a variety of colon 
cancer cell lines. There is a potential for FA to influence EMT in lung cancer cells, but 
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the relationship must be explored through future research. Our data may have future 
implications on whether other countries will adopt a mandatory FA fortification program 
to prevent certain health complications. In addition, the use of anti-folate medications 
may not be beneficial for colon cancer patients with adenocarcinomas.  
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4.2 Conclusion and Future Perspectives  
 More research should be conducted to confirm the conclusion that FA 
supplementation does not affect CRC risk. In our study, we analyzed the effect of FA in 
vitro by treating adenocarcinoma colon cancer cells. Unfortunately, in vitro studies are 
not conducted in the same environment as the intact organism and may produce different 
results. Therefore, an in vivo study in mice should be directed to further analyze the effect 
of FA on CRC. This study could be conducted in healthy mice, and in mice with current 
colon neoplasms. A study should also analyze the effect of FA in healthy human colon 
cells. They could conduct a similar in vitro study, but treat healthy cells with different 
levels of FA and observe any morphological changes that occur. This could give further 
insight into the proper RDA of FA that would optimally reduce colon cancer risk in the 
future.  
 In addition, studies should examine the effect of FA on cells in the early stages of 
cancer development. Unfortunately, colon cell lines in the early (adenoma) stages of 
cancer development are not available. Therefore, a similar study could be conducted in 
breast cancer cells. Normal breast cells, adenoma cells, and adenocarcinoma cells could 
be treated with different levels of FA and cell proliferation could be measured. This 
would be a sufficient model to observe the potential dual effects of FA depending on the 
stage of cancer development.  
 Further research should investigate the effect of FA and its metabolites on EMT 
and cancer cell metastasis. In our study, we analyzed EMT through TGF-β signaling in 
lung cancer cells. A potential experiment to further this data would be to analyze 
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pathways involved with tumor necrosis factor-alpha (TNF-α) in colon cancer cells. TNF-
α is a pro-inflammatory cytokine known to enhance metastatic properties in colon cancer 
cells (44). Analyzing the relationship between FA and metastatic induction via TNF-α 
could provide promising new research. These efforts will continue to expand the 
scientific community’s understanding of factors related to the reduction of cancer 
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